Literature DB >> 27003417

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Kun-Ju Lin1,2, Ing-Tsung Hsiao3,4, Jung-Lung Hsu5,6, Chin-Chang Huang7, Kuo-Lun Huang7, Chia-Ju Hsieh3,4, Shiaw-Pyng Wey3,4, Tzu-Chen Yen3,4.   

Abstract

PURPOSE: We investigated dual-phase (18)F-florbetapir (AV-45/Amyvid) PET imaging for the concomitant detection of brain perfusion deficits and beta-amyloid deposition in patients with Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI), and in cognitively healthy controls (HCs).
METHODS: A total of 82 subjects (24 AD patients, 44 MCI patients and 14 HCs) underwent both dual-phase (18)F-AV-45 PET and MRI imaging. Dual-phase dynamic PET imaging consisted of (1) five 1-min scans obtained 1 - 6 min after tracer injection (perfusion (18)F-AV-45 imaging, pAV-45), and (2) ten 1-min scans obtained 50 - 60 min after tracer injection (amyloid (18)F-AV-45 imaging). Amyloid-negative MCI/AD patients were excluded. Volume of interest analysis and statistical parametric mapping of pAV-45 and (18)F-AV-45 images were performed to investigate the perfusion deficits and the beta-amyloid burden in the three study groups. The associations between Mini-Mental State Examination (MMSE) scores and global perfusion deficits and amyloid deposition were investigated with linear and segmental linear correlation analyses.
RESULTS: HCs generally had normal pAV-45 findings, whereas perfusion deficits were evident in the hippocampus, and temporal, parietal and middle frontal cortices in both MCI and AD patients. The motor-sensory cortex was relatively preserved. MMSE scores in the entire study cohort were significantly associated with the degree of perfusion impairment as assessed by pAV-45 imaging (r = 0.5156, P < 0.0001). (18)F-AV-45 uptake was significantly higher in AD patients than in the two other study groups. However, the correlation between MMSE scores and (18)F-AV-45 uptake in MCI patients was more of a binary phenomenon and began in MCI patients with MMSE score 23.14 when (18)F-AV-45 uptake was higher and MMSE score lower than in patients with early MCI. Amyloid deposition started in the precuneus and the frontal and temporal regions in early MCI, ultimately reaching the maximum burden in advanced MCI.
CONCLUSION: Our results indicate that brain perfusion deficits and beta-amyloid deposition in AD follow different trajectories that can be successfully traced using dual-phase (18)F-AV-45 PET imaging.

Entities:  

Keywords:  18F-Florbetapir (AV-45/Amyvid); Alzheimer’s disease; Amyloid; Dementia; Dual-phase scan; Mild cognitive impairment; Perfusion deficits

Mesh:

Substances:

Year:  2016        PMID: 27003417     DOI: 10.1007/s00259-016-3359-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  48 in total

1.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

Review 2.  Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI.

Authors:  M Jueptner; C Weiller
Journal:  Neuroimage       Date:  1995-06       Impact factor: 6.556

3.  Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease.

Authors:  Erik S Musiek; Yufen Chen; Marc Korczykowski; Babak Saboury; Patricia M Martinez; Janet S Reddin; Abass Alavi; Daniel Y Kimberg; David A Wolk; Per Julin; Andrew B Newberg; Steven E Arnold; John A Detre
Journal:  Alzheimers Dement       Date:  2011-10-21       Impact factor: 21.566

4.  Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

Authors:  A Bozzao; R Floris; M E Baviera; A Apruzzese; G Simonetti
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

5.  Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.

Authors:  Philipp T Meyer; Sabine Hellwig; Florian Amtage; Christof Rottenburger; Ursula Sahm; Peter Reuland; Wolfgang A Weber; Michael Hüll
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

6.  GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.

Authors:  Cheng-Hsiang Yao; Kun-Ju Lin; Chi-Chang Weng; Ing-Tsung Hsiao; Yi-Shu Ting; Tzu-Chen Yen; Tong-Rong Jan; Daniel Skovronsky; Mei-Ping Kung; Shiaw-Pyng Wey
Journal:  Appl Radiat Isot       Date:  2010-07-07       Impact factor: 1.513

7.  Concordance and discordance between brain perfusion and atrophy in frontotemporal dementia.

Authors:  Soichiro Shimizu; Yu Zhang; Joel Laxamana; Bruce L Miller; Joel H Kramer; Michael W Weiner; Norbert Schuff
Journal:  Brain Imaging Behav       Date:  2010-03       Impact factor: 3.978

8.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

9.  Brain imaging evidence of preclinical Alzheimer's disease in normal aging.

Authors:  William Jagust; Amy Gitcho; Felice Sun; Beth Kuczynski; Dan Mungas; Mary Haan
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

10.  Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.

Authors:  Christian Habeck; Shannon Risacher; Grace J Lee; M Maria Glymour; Elizabeth Mormino; Shubhabrata Mukherjee; Sungeun Kim; Kwangsik Nho; Charles DeCarli; Andrew J Saykin; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

View more
  15 in total

Review 1.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

2.  Dual-phase amyloid PET: hitting two birds with one stone.

Authors:  Garibotto Valentina; Morbelli Silvia; Pagani Marco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-23       Impact factor: 9.236

3.  Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Miles N Wernick; Stephen C Strother; Mark E Schmidt
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-08

4.  Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology.

Authors:  Kuan-Yi Wu; Kun-Ju Lin; Chia-Hsiang Chen; Chia-Yih Liu; Yi-Ming Wu; Cheng-Sheng Chen; Tzu-Chen Yen; Ing-Tsung Hsiao
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

Review 5.  18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.

Authors:  Luca Filippi; Agostino Chiaravalloti; Oreste Bagni; Orazio Schillaci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

6.  Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET.

Authors:  Jochen Hammes; Isabel Leuwer; Gérard N Bischof; Alexander Drzezga; Thilo van Eimeren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

7.  Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study.

Authors:  Min Wang; Zhuangzhi Yan; Huiwei Zhang; Jiaying Lu; Ling Li; Jintai Yu; Jian Wang; Hiroshi Matsuda; Chuantao Zuo; Jiehui Jiang
Journal:  Quant Imaging Med Surg       Date:  2021-01

8.  Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Chia-Hsiang Chen; Chia-Yih Liu; Jung-Lung Hsu; Sheng-Yao Huang; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

9.  Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.

Authors:  Nelly Joseph-Mathurin; Yi Su; Tyler M Blazey; Mateusz Jasielec; Andrei Vlassenko; Karl Friedrichsen; Brian A Gordon; Russ C Hornbeck; Lisa Cash; Beau M Ances; Thomas Veale; David M Cash; Adam M Brickman; Virginia Buckles; Nigel J Cairns; Carlos Cruchaga; Alison Goate; Clifford R Jack; Celeste Karch; William Klunk; Robert A Koeppe; Daniel S Marcus; Richard Mayeux; Eric McDade; James M Noble; John Ringman; Andrew J Saykin; Paul M Thompson; Chengjie Xiong; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  Alzheimers Dement (Amst)       Date:  2018-09-27

10.  Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies.

Authors:  Paul C Donaghy; Michael J Firbank; Alan J Thomas; Jim Lloyd; George Petrides; Nicola Barnett; Kirsty Olsen; John T O'Brien
Journal:  Mov Disord       Date:  2018-04-19       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.